175867-01-3

Basic information

• Product Name: Cyclohexanamine, 4-(2-methoxyethoxy)-, trans- (9CI)
• Synonyms: Cyclohexanamine, 4-(2-methoxyethoxy)-, trans- (9CI);trans-4-(2-Methoxyethoxy)cyclohexanamine;(1r,4r)-4-(2-methoxyethoxy)cyclohexanamine(WX191438)
• CAS NO: 175867-01-3
• Molecular Formula: C9H19NO2
• Molecular Weight: 173.25266
• Product Categories: METHOXY
• Mol File: 175867-01-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 241.0±30.0 °C(Predicted)
• Appearance: /
• Density: 0.98±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.37±0.70(Predicted)
• CAS DataBase Reference: Cyclohexanamine, 4-(2-methoxyethoxy)-, trans- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanamine, 4-(2-methoxyethoxy)-, trans- (9CI)(175867-01-3)
• EPA Substance Registry System: Cyclohexanamine, 4-(2-methoxyethoxy)-, trans- (9CI)(175867-01-3)

Safety Data

• Hazardous Substances Data: 175867-01-3(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 

Relevant articles and documents

N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS

The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).

HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38

The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS

The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.